This website is intended for US Healthcare Professionals

CARNITOR® is an approved, safe and effective treatment for carnitine deficiency

Clinically proven to restore normal levels of carnitine in patients with primary and secondary carnitine deficiency, including prevention of carnitine deficiency in end-stage renal disease patients undergoing hemodialysis.

Studies have evaluated the effectiveness of CARNITOR®. 1,2

  • CARNITOR® has been shown to correct the blood levels of carnitine and resolve the impaired transport function of long-chain fatty acids into the mitochondria in carnitine deficiency. Primary carnitine deficiency treatment with CARNITOR® may be expected to improve symptoms associated with this condition.
  • Pharmacokinetic and clinical studies show that administration of CARNITOR® Injection results in increased plasma carnitine concentrations in ESRD patients on hemodialysis.

CARNITOR® is generally well-tolerated and has a favorable safety profile.

There are four presentations or formulations of CARNITOR®

CARNITOR® (levocarnitine) can be administered by injection or orally.

CARNITOR® (levocarnitine) Injection
Injection Recommended Dose
For metabolic disorders
50 mg/kg given as a slow 2- to 3-minute bolus injection or by infusion. Often a loading dose is given to patients with severe metabolic crisis, followed by an equivalent dose over the following 24 hours. It should be administered q3h or q4h, and never less than q6h either by infusion or by intravenous injection. Subsequent daily doses should be in the range of 50 mg/kg or as required. The highest dose administered has been 300 mg/kg.
For ESRD patients on hemodialysis
10 to 20 mg/kg dry body weight as a slow 2- to 3-minute bolus injection into the venous return line after each dialysis session. Dose adjustments should be guided by trough (pre-dialysis) levocarnitine concentrations, and downward dose adjustments (e.g., to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy.
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.

CARNITOR® should be administered intravenously only. Refer to the dosage and administration section of the PI for complete information regarding dosage and administration

Tablets Recommended Dose
Adults
990 mg two or three times a day using the 330 mg tablets, depending on clinical response.
Infants and children
The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day.
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.

Refer to the dosage and administration section of the PI for complete information regarding dosage and administration.

Oral Solution Recommended Dose
Adults
The recommended dosage of levocarnitine is 1 to 3 g/day for a 50 kg subject, which is equivalent to 10 to 30 mL/day of CARNITOR® Oral Solution. Start at 1 g/day (10 mL/day) and increase slowly, assessing tolerance and therapeutic response. Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be of benefit.
Infants and children
The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day.
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.

Refer to the dosage and administration section of the PI for complete information regarding dosage and administration.

Sugar-Free Solution Recommended Dose
Adults
The recommended dosage of levocarnitine is 1 to 3 g/day for a 50 kg subject, which is equivalent to 10 to 30 mL/day of CARNITOR® Sugar-Free Oral Solution. Start at 1 g/day (10 mL/day) and increase slowly, assessing tolerance and therapeutic response. Higher doses should be administered only with caution and only where clinical and biochemical considerations make it seem likely that higher doses will be of benefit.
Infants and children
The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day.
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.

Refer to the dosage and administration section of the PI for complete information regarding dosage and administration.

Find out if CARNITOR® may be the right solution for your patients with carnitine deficiency.

LEARN MORE

CARNITOR® (levocarnitine) Injection full prescribing information.

CARNITOR® (levocarnitine) Tablets, Oral Solution, and Sugar-Free Oral Solution full prescribing information. 

Sources

  1. CARNITOR® (levocarnitine) Injection Prescribing Information. Rockville, MD. Leadiant Biosciences, Inc. Current approved version.
  2. CARNITOR® (levocarnitine) Tablets; Oral Solution; Sugar-Free Oral Solution Prescribing Information. Rockville, MD. Leadiant Biosciences, Inc. Current approved version. 

INDICATIONS AND IMPORTANT SAFETY INFORMATION 

Indications  
CARNITOR® (levocarnitine) Tablets, Oral Solution, and Sugar-Free Oral Solution are indicated for the treatment of primary systemic carnitine deficiency.
CARNITOR® (levocarnitine) Injection is indicated for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.
CARNITOR® (levocarnitine) Injection, Tablets, Oral Solution, and Sugar-Free Oral Solution are also indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency.

IMPORTANT SAFETY INFORMATION 

Contraindications

None known.

Warnings

Carnitor®(levocarnitine) Tablets, Oral Solution, and Sugar-Free Oral Solution

Hypersensitivity Reactions

Serious hypersensitivity reactions, including rash, urticaria, and facial edema have been reported with oral CARNITOR®. Other serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following intravenous levocarnitine administration, mostly in patients with end stage renal disease undergoing dialysis.

Discontinue use of CARNITOR® and instruct patients to seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.

Carnitor® (levocarnitine) Injection

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following CARNITOR® administration, mostly in patients with end stage renal disease who are undergoing dialysis. Some reactions occurred within minutes after intravenous administration of CARNITOR® .

If a severe hypersensitivity reaction occurs, discontinue CARNITOR® treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering CARNITOR® to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.

Precautions

General

The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine.

Carnitor® (levocarnitine) Tablets, Oral Solution, and Sugar-Free Oral Solution

CARNITOR® (levocarnitine) Oral Solution and CARNITOR® SF (levocarnitine) Sugar-Free Oral Solution are for oral/internal use only.  Not for parenteral use

Gastrointestinal reactions may result from a too rapid consumption of carnitine. CARNITOR® (levocarnitine) Oral Solution and CARNITOR® SF (levocarnitine) Sugar-Free Oral Solution may be consumed alone, or dissolved in drinks or other liquid foods to reduce taste fatigue. They should be consumed slowly and doses should be spaced evenly throughout the day to maximize tolerance.

Drug Interactions

Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.

Adverse Reactions

The following adverse reactions associated with the use of levocarnitine were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliability, or to establish a causal relationship to drug exposure.

Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.

Carnitor® (levocarnitine) Tablets, Oral Solution, and Sugar-Free Oral Solution

Gastrointestinal Reactions: Various mild gastrointestinal complaints have been reported during the long-term administration of oral L- or D,L-carnitine; these include transient nausea and vomiting, abdominal cramps, and diarrhea. Gastrointestinal adverse reactions with CARNITOR® (levocarnitine) Oral Solution or CARNITOR® SF (levocarnitine) Sugar-Free Oral Solution dissolved in liquids might be avoided by a slow consumption of the solution or by a greater dilution. Decreasing the dosage often diminishes or eliminates drug-related patient body odor or gastrointestinal symptoms when present. Tolerance should be monitored very closely during the first week of administration, and after any dosage increases.

Musculoskeletal Reactions: Mild myasthenia has been described only in uremic patients receiving D,L-carnitine.

Hypersensitivity Reactions: Rash, urticaria, and facial edema have been reported with oral CARNITOR® (see WARNINGS).

Carnitor® (levocarnitine) Injection

Gastrointestinal Reactions: Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. An incidence for these reactions is difficult to estimate due to the confounding effects of the underlying pathology.

Hypersensitivity reactions: Anaphylaxis, laryngeal edema and bronchospasm (see WARNINGS).

To report SUSPECTED ADVERSE REACTIONS, contact Leadiant Biosciences, Inc. at 1-888-393-4584 or by email at drugsafety@leadiant.com or contact the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.

The risk information provided here is not comprehensive. Refer to the full FDA-approved product labeling.

© 2024, Leadiant Biosciences, Inc.

US-CAR-IV-2300007 V1

US-CAR-IV-2400002 V1

The website you are visiting is intended to provide information for U.S. healthcare professionals.
Yes, I am a healthcare professional residing in the US
No, I am not a healthcare professional residing in the US

You are now leaving the CARNITOR website and entering the Leadiant Biosciences, Inc. US website. The information is intended for US audience only.

GO BACK
CONTINUE

You are now leaving the CARNITOR website and entering the Leadiant Biosciences, Inc. US website. The information is intended for US audience only.

GO BACK
CONTINUE
By entering this information, I confirm that I am a healthcare professional at least 18 years of age, and that I agree to be contacted. I understand that my phone number and/or email address will be used for this purpose and that my contact information will not be used or shared with third parties (except as may be necessary to fulfill my request to receive updates regarding CARNITOR as well as other medical or product updates). I understand that my consent is not required or a condition of purchasing any products and services. We are collecting personal information in order to fulfill your personal request. Please see Leadiant Biosciences, Inc. Privacy Policy here.
 
I also understand that to the extent that I have opted-out of communications via the American Medical Association Physician Data Restriction Program, my consent provided here will prevail with respect to the communications described above.
ACKNOWLEDGE & CONTINUE >
Cookies are pieces of data created when you visit a website. They are stored on your computer and are sent back to the website or to another website that recognizes the cookie. For more information please refer to our cookie policy.
Click here to accept these terms

You are about to leave CARNITOR.com and visit an external site. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE